Bicara Therapeutics Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. We are going to go ahead and get started. I am Stephen Willey, one of the Senior Biotech Analysts here at Stifel. Glad to have with us Ryan Cohlhepp, who is the CEO of Bicara Therapeutics. We are just going to have a casual discussion. If anyone has a question, feel free to raise your hand, and we will get you acknowledged and your question answered. Ryan, thanks for being here. Anything you want to say from an opening statement perspective before we jump into Q&A?
Yeah, sure. Maybe just, I think, step back and ground, for those who may not be as familiar with the Bicara story, is our lead program that we have been developing over the last several years is ficerafusp alfa. It is an EGFR/TGF-β trap that we are developing in a pivotal study in recurrent metastatic head and neck cancer. As we go back to even the design of that molecule and what we were looking to accomplish is TGF-β, for almost 40 years now, has been considered a target that should work. I think there have been many in oncology, TGF-β is one of them. I think there were some notable failures, one of which Merck KGaA had bintrafusp alfa, which was a PD-L1 TGF-β. When we were designing the molecule, we thought that the shortcoming with TGF-β was getting adequate levels of it to the tumor.
Thought if we are able to localize and direct it to the tumor, we could see activity that ultimately fulfill the promise of TGF-β and the biology, the underlying biology. I think we have absolutely been able to do that. What we have demonstrated in the head and neck population, the ability to just to almost triple response rates. We have got mature follow-up in our phase I cohorts now out to beyond three years, where we are showing a median overall survival in an HPV-negative population of close to 22 months, which is 10 months greater than what you see with the standard of care right now. At the three-year mark, we have been able to demonstrate that we have twice as many patients alive at the three-year mark that would have been alive otherwise with KEYTRUDA.
I think that was all, that data was the basis for investing in and initiating the pivotal trial, the FORTIFI-HN01 trial, which we are anticipating data, top line, middle of next year, which we are really excited about. Again, based on the data that we have seen for ourselves and the class in general, do believe that we have a profile based on the depth and durability that TGF-β delivers, that will allow us to show meaningful and a best-in-class overall survival profile.
Okay, great. I generally don't like to start off talking about other people's drugs during these things.
Let's do it. Let's do it.
Just given that seems like a very appropriate place to start here, given the Genmab disclosure from a couple weeks ago. How are you and, I guess, your team just interpreting kind of the headline response rate and OS statistics that were provided in the phase III frontline trial press release? We'll have some follow-ups from there.
Yeah. With that release, again, I think there was a fairly limited data that Genmab put out there. As we've evaluated that, both in terms of what we believe that data tells us from a differentiation perspective and how we ultimately will stack up against the petosemtamab molecule. But also, probably even more importantly, is what can we read through as we think about our own study, what we want to do, how we're executing, and how we're operationalizing the FORTIFI-HN01 study. At the end of the day, we can only control what we can control, and the conduct of the FORTIFI trial is one of those things. As we look at that, the two key pieces of data were on response rate. They chose to present the data based on an odds ratio, so you have to make some assumptions based on the control arm.
What we did hear from Genmab is that it was consistent with what you've seen historically with pembro as a control arm in these types of trials. I think the range that we would model there would be somewhere between 19% and 25% on a response rate basis. What that tells us is it's likely that in a blended population, and again, that's a key difference between our trial and the Genmab trial, is based upon historical data, we made the strategic decision to develop an HPV-negative population alone. We felt that both the data from our own trial as well as the historical data that was prospectively evaluated across multiple trials with EGFR monoclonal antibodies suggests that these molecules aren't going to work as well on HPV-positive patients. We chose to develop it in the population where we expect the most profound benefit.
When you look at, in that pooled population, we fully anticipate the inclusion of the HPV-positive will cause some level of deterioration in the response rate data. But what that data tells us is that even in an HPV-negative population where you're trying to compare apples to apples, you probably have seen in that trial petosemtamab delivering data consistent with what they had seen previously, probably in the mid-50s, maybe into the low 60% range on a response rate perspective. I think again, one of the scenarios that could have played out was they put up a big number in the 70s for HPV-negative. Again, we think that that scenario is very unlikely based on the data that we saw.
As you move to overall survival, which I think that's where the market has shifted to and their focus around how are these drugs ultimately going to differentiate in survival. What we saw is a hazard ratio of 0.5, but not much beyond that. The confidence intervals that they showed would suggest that it was a fairly early analysis with about 175 death events in a total trial of 700 patients. But we don't know how many of those death events were in HPV-positive patients versus HPV-negative patients, which we know will have a significant influence ultimately in what that looks like. You also think about where, if you look at the KEYNOTE-048 trial, which was a study that Merck had to support the approval of pembro in this population, the Kaplan-Meier shows a pretty aggressive decline in the first 30% to 40% of patients.
Our view, based on the number of events that are in the current analysis, is you're probably on the front end of the curve. As you think about these agents, particularly IO-based therapies, TGF-β in particular, as you think about where is that contribution going to come from, I think you start to see in the later phases of the curve. I would say even as you think about where HPV-positive patients are likely to sit in that curve, we know that HPV-positive patients live longer.
We do think that there's a high probability that that hazard ratio will deteriorate over time, which I think as you play that forward from a regulatory path perspective, I think the jury is still out in terms of ultimately what the initial approval or label will look like for petosemtamab. That being said, as we read that through to our own trial, we've got greater confidence in an ability to see a statistically significant benefit with a smaller sample size. As we think about the allocation of alpha and where you spend it, one of the things at earnings this week we communicated is we committed to an interim analysis for overall survival.
I think we've got additional data to inform the way we think about that, which, I'd much rather have that data now, when we still have runway on these decisions, versus seeing it on the other side of a top line where I think we came out of that with more information for us to inform our own strategy.
Maybe you can talk a little bit about the interim analysis that you're now committed to conducting on survival and just, I think a lot of the questions that we get now is, okay, how is this going to align with the response rate interim analysis that I think you've pre-specified based upon a 350 or so patient fraction? You do have, as you said, exclusively HPV-negative patients in this trial. Presumably, historical outcomes would suggest that you're going to accrue death events faster. Do you think that there's an opportunity whereby you can get to that event trigger number that informs an interim by time of the response rate look?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
